

# DOLPHIN MEDICAL SERVICES LIMITED

#417, Sanali Heavens, Ameerpet, HYDERABAD – 500 073, Telangana, India

Phone/Fax:+91-40-23738877, Email: [dolphinmedicalindia@gmail.com](mailto:dolphinmedicalindia@gmail.com)

[www.dolphinmedicalservices.com](http://www.dolphinmedicalservices.com), CIN:L24239TG1992PLC014775

.....

Date: 14.02.2022

To  
The Manager  
Department of Corporate Services  
**BOMBAY STOCK EXCHANGE LTD.**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

**SCRIP CODE: 526504**

Dear Sir,

Sub: **Submission of Unaudited Financial Results for the 3<sup>rd</sup> Quarter and Nine months ended 31.12.2021 – Reg.**

Ref: Our letter dated 02.02.2022

With reference to the above and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are herewith submitting Unaudited Financial Results for the 3<sup>rd</sup> Quarter and Nine months ended 31.12.2021 along with Limited Review Report. The results were reviewed by the Audit Committee and approved and taken on record by the Board of Directors at their meeting held on 14<sup>th</sup> February 2022.

The Meeting of the Board commenced at 04.00 P.M. and concluded at 04.50 P.M.

This is for the information and records of the Exchange.

Thanking You Sir

Yours faithfully  
for **DOLPHIN MEDICAL SERVICES LIMITED**



**Dr. MOHAN PRASAD GV**

Managing Director

DIN: 01236113

Encl.s:

1. Unaudited Financial Results for the 3<sup>rd</sup> Quarter and Nine months ended 31.12.2021
2. Limited Review Report

# DOLPHIN MEDICAL SERVICES LIMITED

# 417, SANALI HEAVENS, AMEERPET, HYDERABAD - 500 073, TELANGANA  
**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2021**

CIN: L24239TG1992PLC014775, email: dolphincomplianceofficer@gmail.com

(Prepared in compliance with the Indian Accounting Standards (Ind AS))

(Amount Rs. in Lakhs)

S. No.	PARTICULARS	QUARTER ENDED 31.12.2021 UNAUDITED	QUARTER ENDED 30.09.2021 UNAUDITED	QUARTER ENDED 31.12.2020 UNAUDITED	NINE MONTHS ENDED 31.12.2021 UNAUDITED	NINE MONTHS ENDED 31.12.2020 UNAUDITED	FINANCIAL YEAR ENDED 31.03.2021 AUDITED
1	<b>Revenue from Operations</b>						
	Revenue from Operations	16.57	14.93	16.04	41.79	37.84	47.31
	Other Income	0.92	0.92	0.92	2.76	2.84	555.19
	<b>Total Revenue (I + II)</b>	<b>17.49</b>	<b>15.85</b>	<b>16.96</b>	<b>44.55</b>	<b>40.68</b>	<b>602.50</b>
2	<b>Expenses</b>						
a	Cost of Materials consumed	2.31	2.14	1.27	5.82	2.87	4.16
b	Purchases of stock-in-trade	-	-	-	-	-	-
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
d	Employee benefit expense	2.05	2.16	0.65	5.86	1.90	6.41
e	Finance costs	0.23	0.24	0.26	0.72	0.73	0.97
f	Depreciation and amortisation expense	1.57	1.57	1.61	4.71	4.83	6.35
g	Other Expenses	14.26	17.58	11.43	39.30	35.47	614.18
	<b>Total expenses</b>	<b>20.42</b>	<b>23.69</b>	<b>15.22</b>	<b>56.41</b>	<b>45.80</b>	<b>632.07</b>
3	<b>Profit/(Loss) before exceptional items and tax</b>	<b>(2.93)</b>	<b>(7.84)</b>	<b>1.74</b>	<b>(11.86)</b>	<b>(5.12)</b>	<b>(29.57)</b>
4	Exceptional items	-	-	-	-	-	-
5	<b>Profit/(Loss) before tax</b>	<b>(2.93)</b>	<b>(7.84)</b>	<b>1.74</b>	<b>(11.86)</b>	<b>(5.12)</b>	<b>(29.57)</b>
6	<b>Tax Expense</b>						
7	Current tax	-	-	-	-	-	-
8	Deferred tax	-	-	-	-	-	1.65
9	<b>Total tax expenses</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1.65</b>
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	-	-	-	-	-	-
11	<b>Net Profit/(Loss) for the period from continuing operations</b>	<b>(2.93)</b>	<b>(7.84)</b>	<b>1.74</b>	<b>(11.86)</b>	<b>(5.12)</b>	<b>(31.22)</b>
12	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-	-
13	Tax expense of discontinued operations	-	-	-	-	-	-
14	Net Profit/(Loss) for the period from discontinued operations after Tax	-	-	-	-	-	-
15	<b>Net Profit/(Loss) for the period</b>	<b>(2.93)</b>	<b>(7.84)</b>	<b>1.74</b>	<b>(11.86)</b>	<b>(5.12)</b>	<b>(31.22)</b>
16	Other comprehensive income net of taxes	-	-	-	-	-	-
17	<b>Total Comprehensive Income/(Loss) for the period</b>	<b>(2.93)</b>	<b>(7.84)</b>	<b>1.74</b>	<b>(11.86)</b>	<b>(5.12)</b>	<b>(31.22)</b>
18	<b>Details of equity share capital</b>						
	Paid-up equity share capital	1,509.99	1,509.99	1,509.99	1,509.99	1,509.99	1,509.99
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
19	<b>Reserves excluding revaluation reserve</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(461.05)</b>
	Debenture redemption reserve	-	-	-	-	-	-
20	<b>Earnings per equity share for continuing operations</b>						
	Basic earnings (loss) per share from continuing operations	(0.02)	(0.05)	0.01	(0.08)	(0.03)	(0.21)
	Diluted earnings (loss) per share from continuing operations	(0.02)	(0.05)	0.01	(0.08)	(0.03)	(0.21)

By Order of the Board  
for DOLPHIN MEDICAL SERVICES LIMITED



Dr. MOHAN PRASAD GV  
Managing Director  
DIN: 01236113

21	<b>Earnings per equity share for discontinued operations</b>						
	Basic earnings (loss) per share from discontinued operations	-	-	-	-	-	-
	Diluted earnings (loss) per share from discontinued operations	-	-	-	-	-	-
22	<b>Earnings per equity share</b>						
	Basic earnings (loss) per share from continuing and discontinued operations	(0.02)	(0.05)	0.01	(0.08)	(0.03)	(0.21)
	Diluted earnings (loss) per share from continuing and discontinued operations	(0.02)	(0.05)	0.01	(0.08)	(0.03)	(0.21)
23	Public Share Holding:						
	i) Number of Shares	11,107,651	11,107,651	11,107,651	11,107,651	11,107,651	11,107,651
	ii) Percentage of Share Holding	73.56%	73.56%	73.56%	73.56%	73.56%	73.56%
24	Promoters and Promoter group						
	Share holding						
	a) Pledged/Encumbered						
	- Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a %age of total share holding of promoter and promoter group)	N.A	N.A	N.A	N.A	N.A	N.A
	- Percentage of shares (as a %age of total share capital of the company)	N.A	N.A	N.A	N.A	N.A	N.A
	b) Non-encumbered						
	- Number of Shares	3,992,301	3,992,301	3,992,301	3,992,301	3,992,301	3,992,301
	- Percentage of shares (as a %age of total share holding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a %age of total share capital of the company)	26.44%	26.44%	26.44%	26.44%	26.44%	26.44%

Particulars	Quarter ended 31st December 2021
<b>B Investor Complaints</b>	
1 Pending at the beginning of the Quarter	NIL
2 Received during the quarter	NIL
3 Disposed off during the quarter	NIL
4 Remaining unresolved at the end of the quarter	NIL

Notes :

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 14th February 2022.
- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies (Indian Accounting Standard) Rules 2015, and other recognised accounting principles generally accepted in India.

Place: Hyderabad

Date : 14.02.2022

By Order of the Board  
for DOLPHIN MEDICAL SERVICES LIMITED



Dr. MOHAN PRASAD GV  
Managing Director  
DIN: 01236113

**PINNAMANENI & CO.**  
Chartered Accountants



3 & 4, RAM'S VSR APARTMENTS  
Moghalrajpuram, VIJAYAWADA-520 010  
Andhra Pradesh, India

**LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS FOR THE**  
**3<sup>rd</sup> QUARTER AND NINE MONTHS ENDED 31<sup>st</sup> DECEMBER 2021**

Review Report to  
The Board of Directors  
**M/s. Dolphin Medical Services Limited**  
#417, Sanali Heavens, Ameerpet  
**HYDERABAD** – 500 073

We have reviewed the accompanying statement of unaudited financial results of M/s. Dolphin Medical Services Limited for the 3<sup>rd</sup> Quarter and Nine Months ended 31<sup>st</sup> December 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of the Regulation 33 of The SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.

This Statement, which is responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement of financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date : 14.02.2022

for **PINNAMANENI & Co.,**  
Chartered Accountants  
(Firm Registration No.002661S)

**P. Avinash**

**CA P. AVINASH**  
Partner  
Membership No. 236268